{"brief_title": "Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease", "brief_summary": "The purpose of this study is to determine whether darbepoetin alfa manufactured by the current \"roller bottle\" technology and darbepoetin alfa manufactured by a serum free process have a comparable safety profile.", "condition": "Chronic Kidney Disease", "intervention_type": "Drug", "intervention_name": "darbepoetin alfa SF", "description": "Frequency of dosing depends on frequency at randomization:\nrHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL", "arm_group_label": "darbepoetin alfa SF", "criteria": "Inclusion Criteria: - Currently diagnosed with Chronic Kidney Disease, either receiving or not receiving dialysis - Anemic - Currently on erythropoietic therapy - Controlled hypertension - Clinically stable", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00093977.xml"}